Overview +

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s LeukoCore™ RUO leukopaks provide a high concentration of immune cells from a single donor as the white blood cells are extracted from the peripheral blood. Billions of cells from a single donor offer a reliable and consistent source of high-quality immune cells for drug development, cell therapy, and immunology research. Available fresh or cryopreserved in full- and half-packs, our leukopaks are collected directly from our extensive Donor Network, allowing us to recruit, screen, and recall donors to meet complex inclusion and exclusion (I/E) criteria. Sanguine’s LeukoCore™ RUO leukopaks are collected on the Spectra Optia® Apheresis System. Our leukopaks include donor demographics, verified conditions via donor electronic medical records, and infectious disease testing. Donors are recallable, and screening donors before purchasing a half- or full-pack is an option with LeukoLots™. HLA typing is available for an additional fee.

Well-characterized leukopaks for asthma research supports studies on airway inflammation, immune response, and therapeutic development to advance understanding and treatments for this chronic respiratory disease.

Infectious disease testing requirements differ globally. If you are ordering from outside the U.S., please reach out at to confirm that we can meet your country’s regulatory and documentation needs.